Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1981 to 1995 of 8904 results

  1. Dersimelagon for treating erythropoietic protoporphyria and X-linked protoporphyria in people 12 years and over [ID6160]

    In development Reference number: GID-TA11085 Expected publication date: TBC

    Technology appraisal guidance
    In development

  2. Belzutifan with lenvatinib for treating advanced renal cell carcinoma after a PD-1 or PD-L1 inhibitor [ID6476]

    In development Reference number: GID-TA11584 Expected publication date:  08 December 2027

    Technology appraisal guidance
    In development

  3. Triheptanoin for treating long-chain fatty acid oxidation disorders [ID3891]

    In development Reference number: GID-TA11473 Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]

    In development Reference number: GID-TA11699 Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Nivolumab with BMS-986205 and chemotherapy for neoadjuvant treatment of muscle-invasive bladder cancer [ID6321]

    In development Reference number: GID-TA11336 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Diabetes in pregnancy: management from preconception to the postnatal period - Managing type 1 diabetes (T1D) using hybrid closed loops (update)

    In development Reference number: GID-NG10450 Expected publication date: TBC

    NICE guideline
    In development

  7. Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]

    Awaiting development Reference number: GID-TA10662 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Implanting a baroreceptor stimulation device for resistant hypertension

    In development Reference number: GID-IP1180 Expected publication date: TBC

    Interventional procedures guidance
    In development

  9. Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma

    In development Reference number: GID-IPG10067 Expected publication date: TBC

    Interventional procedures guidance
    In development

  10. Total hip arthroplasty using the superpath approach for osteoarthritis

    In development Reference number: GID-IPG10204 Expected publication date: TBC

    Interventional procedures guidance
    In development

  11. Oveporexton for treating type 1 narcolepsy [ID6622]

    Awaiting development Reference number: GID-TA11820 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    In development Reference number: GID-TA10868 Expected publication date:  15 July 2026

    Technology appraisal guidance
    In development

  13. Zimislecel for treating type 1 diabetes in people 12 years and over with impaired hypoglycaemic awareness and severe hypoglycaemia [ID6624]

    Awaiting development Reference number: GID-TA11816 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Talquetamab with daratumumab for treating relapsed or refractory multiple myeloma after 1 or more lines of treatment including a proteasome inhibitor and lenalidomide [ID6625]

    Awaiting development Reference number: GID-TA11815 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Psoriasis: assessment and management (CG153)

    In development Reference number: GID-NG10448 Expected publication date: TBC

    NICE guideline
    In development